CAM
STOK icon

Cresset Asset Management’s Stoke Therapeutics STOK Stock Holding History

Cresset Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$799K Sell
24,411
-83
-0.3% -$2.66K ﹤0.01% 999
2026
Q1 		$798K Sell
24,494
-1,831
-7% -$60K ﹤0.01% 881
2025
Q4 		$836K Sell
26,325
-411
-2% -$12.4K ﹤0.01% 861
2025
Q3 		$628K Buy
+26,736
New +$458K ﹤0.01% 928

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cresset Asset Management's STOK Position: Q2 2026 in Review

Cresset Asset Management reduced its Stoke Therapeutics (STOK) stake by 0.34% in Q2 2026, selling an estimated $2.66K and leaving 24,411 shares worth $799K. The position accounts for ﹤0.01% of the portfolio, ranked #999.

Cresset Asset Management first reported a position in STOK in Q3 2025 and has held it in 4 quarters since. The position peaked at $836K in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Cresset Asset Management held 24,411 shares of Stoke Therapeutics worth $799K as of Q2 2026.
  • Cresset Asset Management sold 83 Stoke Therapeutics shares in Q2 2026, an estimated $2.66K.
  • Stoke Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #999 holding.
  • Cresset Asset Management first reported a position in Stoke Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Cresset Asset Management's Stoke Therapeutics position peaked at $836K in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.